Oncology Pharma, Inc. Has Engaged a PCAOB Audit Firm Looking Towards Moving the Company Towards a Senior Listing
15 Octobre 2021 - 4:51PM
InvestorsHub NewsWire
San Francisco, CA. -- October
15, 2021 -- InvestorsHub NewsWire -- Oncology Pharma
Inc. (OTC:
ONPH) Pursuant to previously announced press release, Oncology
Pharma, Inc. (the "Company") has retained the services of
DBBMcKennon, LLC, a PCAOB Certified Public Accounting Firm.
The Company has retained the firm to conduct an audit of its
financials in order to become compliant with SEC reporting
standards as it look towards its intended NASDAQ Capital Markets
Listing. The management team has been diligently working
towards positioning the Company into a setting where it can support
the momentum, growth and movement of the Company as it looks
towards the future.
DBBMcKennon is a
full-service, PCAOB Registered Certified Public
Accounting firm, providing audit, tax,
and consulting services to individuals and businesses through
its offices located in Newport Beach, San Diego, and Santa
Monica, CA.
A spokesman from the Company stated "we are excited to be working
with DBBMcKennon and the prospect of an uplisting". More to
follow as material events become available.
ABOUT ONCOLOGY PHARMA,
INC.
ONCOLOGY PHARMA, INC. (OTCPK:
ONPH) (the "Company") is currently engaging in research and
development of therapeutics for oncology and prides itself for
having a world-class Advisory Board that keeps the Company in the
forefront of developing technologies in cancer research,
biotechnology, and healthcare.
FORWARD LOOKING
STATEMENTS
Certain of the matters discussed in
this announcement contain forward-looking statements that involve
material risks to and uncertainties in the Company's business that
may cause actual results to differ materially from those
anticipated by the statements made herein. Such risks and
uncertainties include risks related to licensing arrangements and
joint ventures, including the need to negotiate the definitive
agreements for the relationships; possible failure to realize
anticipated benefits of business relationships; and, costs of
providing funding to these business relationships. Other risks and
uncertainties relating to the Company include, among other things,
current negative operating cash flows and a need for additional
funding to finance our operating plan; the terms of any further
financing, which may be highly dilutive and may include onerous
terms; unexpected costs and operating deficits, and lower than
expected sales and revenues; uncertain willingness and ability of
customers to adopt new technologies and other factors that may
affect further market acceptance; adverse economic conditions;
adverse results of any legal proceedings; the volatility of our
operating results and financial condition; inability to attract or
retain qualified senior management personnel, including sales and
marketing personnel; our ability to establish and maintain the
proprietary nature of our technology through the patent process, as
well as our ability to possibly license from others patents and
patent applications necessary to develop products; the Company's
ability to implement its long range business plan for various
applications of its technology; the Company's ability to enter into
agreements with any necessary marketing and/or distribution
partners and with any strategic or joint venture partners; the
impact of competition; the obtaining and maintenance of any
necessary regulatory clearances applicable to applications of the
Company's technology; management of growth; and, other risks and
uncertainties. This is not a solicitation to buy or sell securities
and does not purport to be an analysis of the Company's financial
position.
CONTACTS:
For additional Information, please contact Oncology Pharma at:
One Sansome Street, Suite 3500
San Francisco, CA 94104
Phone: 415-869-1038
Fax: 415-946-8801
Website: www.oncology-pharma.com
Email: info@oncology-pharma.com
Oncology Pharma (CE) (USOTC:ONPH)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Oncology Pharma (CE) (USOTC:ONPH)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Oncology Pharma Inc (CE) (OTCMarkets): 0 recent articles
Plus d'articles sur Oncology Pharma Inc (PK)